Almirall and Eloxx Sign an Exclusive Licensing Agreement for Rare Dermatological Pathologies

Almirall buys the exclusive rights to a possible new treatment from Eloxx Pharmaceuticals. The two companies have signed an exclusive license agreement for the ZKN-013 asset for rare diseases, as reported by the biopharmaceutical company to the National Securities Market Commission (Cnmv) this Wednesday.

Almirall, under the agreement, obtains global rights to develop and commercialize ZKN-013 , including its use in orphan dermatological diseases. Specifically, ZKN-013 is a “potentially promising” orally administered drug that allows host cells to produce functional proteins that counteract the root cause of missense mutations in rare and potentially other dermatological diseases.

This drug candidate is expected to enter “phase I development soon in healthy volunteers,” as Almirall has detailed, while explaining that, under the terms of the agreement, Eloxx will receive an initial payment of three million dollars, and additional payments throughout potential development phases , including “regulatory milestones” and sales of up to $470 million, as well as tiered royalties based on any potential future global sales.

Read more about the agreement between Almirall and Eloxx Pharmaceutical and fidn the most important business news of the day with the Born2Invest mobile app.

Almirall closed 2023 with net losses of 38.5 million euros

However, Almirall has stressed that recessive dystrophic epidermolysis bullosa (Ebdr) and junctional epidermolysis bullosa (JEB) are rare skin diseases characterized by defects in the Collagen7 gene, “essential” for the correct formation of the skin structure. and barrier function.

The biopharmaceutical company commented that ZKN-013 has demonstrated “solid preclinical functional activity” in cells from patients with Ebdr or JEB and in APCmin (multiple intestinal neoplasia) mice. “The studies demonstrated that ZKN-013 induces the production of functional, full-length COL7 in cells from patients with Ebdr and JEB with nonsense mutations for this protein,” Almirall said in a statement.

The Spanish pharmaceutical company recorded net losses of 38.5 million euros in 2023 due to impairment charges associated with the book value of the oral acne antibiotic Seysara. This result was offset on the stock market by the announcement of an exclusive licensing agreement with Novo Nordisk to exploit the rights to the monoclonal antibody NN-8828, which blocks the cytokine IL-21.

Based on this agreement, Almirall obtains global rights to develop and commercialize the Danish pharmaceutical company’s compound in certain indications, including immune-mediated inflammatory dermatological diseases.

__

(Featured image by Kjerstin_Michaela via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us